Top-Rated StocksTop-RatedNASDAQ:WVE Wave Life Sciences (WVE) Stock Price, News & Analysis $6.81 -0.76 (-10.04%) As of 01:16 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Wave Life Sciences Stock (NASDAQ:WVE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Wave Life Sciences alerts:Sign Up Key Stats Today's Range$6.79▼$7.2950-Day Range$7.57▼$12.2452-Week Range$4.25▼$16.74Volume925,808 shsAverage Volume1.14 million shsMarket Capitalization$1.05 billionP/E RatioN/ADividend YieldN/APrice Target$22.60Consensus RatingBuy Company OverviewWave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.Read More… Remove Ads Wave Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreWVE MarketRank™: Wave Life Sciences scored higher than 92% of companies evaluated by MarketBeat, and ranked 62nd out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingWave Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageWave Life Sciences has only been the subject of 2 research reports in the past 90 days.Read more about Wave Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Wave Life Sciences are expected to grow in the coming year, from ($1.14) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Wave Life Sciences is -6.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Wave Life Sciences is -6.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWave Life Sciences has a P/B Ratio of 17.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Wave Life Sciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.71% of the float of Wave Life Sciences has been sold short.Short Interest Ratio / Days to CoverWave Life Sciences has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Wave Life Sciences has recently decreased by 8.95%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldWave Life Sciences does not currently pay a dividend.Dividend GrowthWave Life Sciences does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.58 Percentage of Shares Shorted7.71% of the float of Wave Life Sciences has been sold short.Short Interest Ratio / Days to CoverWave Life Sciences has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Wave Life Sciences has recently decreased by 8.95%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.72 News SentimentWave Life Sciences has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Wave Life Sciences this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for WVE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows9 people have added Wave Life Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Wave Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,720,154.00 in company stock.Percentage Held by Insiders29.10% of the stock of Wave Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.73% of the stock of Wave Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Wave Life Sciences' insider trading history. Receive WVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address WVE Stock News HeadlinesInsider Selling: Wave Life Sciences Ltd. (NASDAQ:WVE) Director Sells 10,500 Shares of StockMarch 22, 2025 | insidertrades.comPaul Bolno Sells 169,025 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) StockMarch 8, 2025 | insidertrades.comYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.April 3, 2025 | Premier Gold Co (Ad)Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE) and Nuvation Bio (NUVB)April 2 at 6:18 PM | markets.businessinsider.comQ1 Earnings Forecast for WVE Issued By Leerink PartnrsApril 1 at 1:17 AM | americanbankingnews.comWave Life Sciences Ltd. (NASDAQ:WVE) Receives $22.60 Average Price Target from AnalystsMarch 31 at 2:18 AM | americanbankingnews.comWave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531March 27, 2025 | seekingalpha.comWave Life Sciences unveils Phase II data for DMD therapy, WVE-N531March 27, 2025 | finance.yahoo.comSee More Headlines WVE Stock Analysis - Frequently Asked Questions How have WVE shares performed this year? Wave Life Sciences' stock was trading at $12.37 on January 1st, 2025. Since then, WVE shares have decreased by 42.6% and is now trading at $7.1040. View the best growth stocks for 2025 here. How were Wave Life Sciences' earnings last quarter? Wave Life Sciences Ltd. (NASDAQ:WVE) announced its earnings results on Tuesday, March, 4th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.34. The company earned $83.75 million during the quarter, compared to analysts' expectations of $25.60 million. Wave Life Sciences had a negative trailing twelve-month return on equity of 280.57% and a negative net margin of 66.50%. How do I buy shares of Wave Life Sciences? Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Wave Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Wave Life Sciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Intel (INTC) and Netflix (NFLX). Company Calendar Last Earnings3/04/2025Today4/03/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:WVE CIK1631574 Webwww.wavelifesciences.com Phone(656) 236-3388Fax617-949-2901Employees240Year FoundedN/APrice Target and Rating Average Stock Price Target$22.60 High Stock Price Target$36.00 Low Stock Price Target$15.00 Potential Upside/Downside+198.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,510,000.00 Net Margins-66.50% Pretax Margin-265.84% Return on Equity-280.57% Return on Assets-52.90% Debt Debt-to-Equity RatioN/A Current Ratio1.90 Quick Ratio1.90 Sales & Book Value Annual Sales$108.30 million Price / Sales10.73 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book18.93Miscellaneous Outstanding Shares153,486,000Free Float108,137,000Market Cap$1.16 billion OptionableOptionable Beta-0.93 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:WVE) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredEU’s Action Takes Aim At US RetireesTrump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Wave Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Wave Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.